Filing Flows › Organon (OGN) › Q2 2026 › vs Q2 2025
Organon (OGN) Q2 2026 vs Q2 2025 (year over year)
Organon's revenue fell $36.0M (-2%) from $1.6B in Q2 2025 to $1.6B in Q2 2026. Gross margin 54.4% against 54.8% (-0.5 pts).
Organon, Q2 2026: revenue $1.6B (-2% year over year), operating margin 11.7%, net earnings $108M, operating cash flow $107M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Gross margin | 54.4% | 54.8% | -0.5 pts |
| Operating margin | 11.7% | 14.4% | -2.6 pts |
| Net margin | 6.9% | 9.1% | -2.2 pts |
| Free cash flow margin | 4.2% | 11.4% | -7.2 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $1.6B | $1.6B | −$36.0M | -2% |
| Gross profit | $847M | $874M | −$27.0M | -3% |
| Cost of revenue | $711M | $720M | −$9.0M | -1% |
| Operating profit | $183M | $229M | −$46.0M | -20% |
| Operating expenses | $664M | $645M | $19.0M | +3% |
| Pre-tax earnings | $183M | $229M | −$46.0M | -20% |
| Research & development | $90.0M | $95.0M | −$5.0M | -5% |
| SG&A | $434M | $453M | −$19.0M | -4% |
| Other operating costs | $140M | $97.0M | $43.0M | +44% |
| Net earnings | $108M | $145M | −$37.0M | -26% |
| Income tax | $75.0M | $84.0M | −$9.0M | -11% |
| Depreciation | $34.0M | $36.0M | −$2.0M | -6% |
| Share-based compensation | $25.0M | $22.0M | $3.0M | +14% |
| Working capital & other | $60.0M | −$17.0M | $77.0M | — |
| Operating cash flow | $107M | $220M | −$113M | -51% |
| Free cash flow (OCF − capex) | $65.0M | $181M | −$116M | -64% |
| Capital expenditures | $42.0M | $39.0M | $3.0M | +8% |
Questions
How much did Organon's revenue grow year over year in Q2 2026?
Organon's revenue fell $36.0M (-2%) from $1.6B in Q2 2025 to $1.6B in Q2 2026. Gross margin 54.4% against 54.8% (-0.5 pts).